BullFrog AI Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $9.92M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
BullFrog AI has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements BullFrog AI filed with the SEC
AI Regains Compliance with Nasdaq Shareholders’ Equity Requirement
Other events · EX-99.1 to Form 8-K
AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with
Other events · EX-99.1 to Form 8-K
AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive
Material agreement · Other events · EX-99.1 to Form 8-K
AI Publishes Annual Letter to Shareholders
Other events · EX-99.1 to Form 8-K
AI Announces Strategic Collaboration with Sygnature Discovery to Introduce BullFrog Data Networks™ to Global Biopharma Clients
Other events · EX-99.1 to Form 8-K
AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial
Other events · EX-99.1 to Form 8-K
AI Issues Letter to Stockholders
Other events · EX-99.1 to Form 8-K
AI Announces Appointment of Chief Financial Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
AI Announces Pricing of Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
AI Announces Closing of Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni
Regulation FD disclosure · EX-99.1 to Form 8-K
AI Announces Publication of Data Supporting Potential of Liver Disease Treatment Candidate BF-114
Regulation FD disclosure · EX-99.1 to Form 8-K
AI and Lieber Institute for Brain Development Reveal New Insights into Bipolar Disorder Pathways and Potential Drug Targets
Regulation FD disclosure · EX-99.1 to Form 8-K
AI and Lieber Institute for Brain Development Collaboration Identifies Novel Drug Targets for Neuropsychiatric Disorders
Regulation FD disclosure · EX-99.1 to Form 8-K
AI’s CSO, Tom Chittenden, to Present at the Quantum Computing Symposium at Bio-IT World Conference & Expo
Regulation FD disclosure · EX-99.1 to Form 8-K
AI Announces Availability of Fireside Chat Recording Featuring CEOs of BullFrog AI and the Lieber Institute
Regulation FD disclosure · EX-99.1 to Form 8-K
AI Appoints Globally Renowned Biomedical AI Expert Dr. Thomas W. Chittenden as Chief Scientific Officer
Regulation FD disclosure · EX-99.1 to Form 8-K
AI to Discuss Findings from its Collaboration with Lieber Institute for Brain Development in Fireside Chat Hosted by RedChip
Regulation FD disclosure · EX-99.1 to Form 8-K
AI Announces Pricing of $5.7 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
AI Announces Closing of $5.7 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
AI Strengthens Scientific Advisory Board with the Addition of Dr. Gwenn Smith and Dr. Jeremiah Wala
Other events · EX-99.1 to Form 8-K
AI’s Collaboration with Lieber Institute for Brain Development Yields Potentially Groundbreaking Biological Stratification of Brain
Regulation FD disclosure · EX-99.1 to Form 8-K
AI Announces Issuance of Australian Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer
Regulation FD disclosure · EX-99.1 to Form 8-K
AI Issues Letter to Shareholders
Regulation FD disclosure · EX-99.1 to Form 8-K
AI Announces Identification of Novel Potential Drug Targets for Colorectal Cancer Using Its AI-Driven bfLEAP™ Platform
Regulation FD disclosure · EX-99.1 to Form 8-K
Investor Relations | Corporate Communications | Clinical Trial Patient Recruitment
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Investor Relations | Corporate Communications | Clinical Trial Patient Recruitment
Regulation FD disclosure · EX-99.1 to Form 8-K
Investor Relations | Corporate Communications | Clinical Trial Patient Recruitment
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
AI Announces Issuance of U.S. Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer
Regulation FD disclosure · EX-99.1 to Form 8-K
AI Announces Appointment of Enrique García-Rivera as Vice President of Artificial Intelligence
Regulation FD disclosure · EX-99.1 to Form 8-K
AI CEO Vin Singh to Present at the Gujarati Physicians Convention 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
AI Strengthens Capabilities of its AI Platform through Expansion of Licensing Agreement with Johns Hopkins Applied Physics Laboratory
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · Executive or director change · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Executive or director change · Other events · EX-99.2 to Form 8-K